Journal
ISCIENCE
Volume 23, Issue 11, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2020.101727
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Sciences (JSPS), Japan [19K16359, 16H05107]
- AMED, Japan [JP19am0101071, 1407]
- Showa Pharmaceutical University, Japan
- JSPS [18K06081]
- Japan Science and Technology Agency, Japan [JPMJTM19AT]
- Photon Factory Program Advisory Committee, Japan [2018G658]
- Grants-in-Aid for Scientific Research [19K16359, 16H05107, 18K06081] Funding Source: KAKEN
Ask authors/readers for more resources
Most triacylglycerol-lowering fibrates have been developed in the 1960s-1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPAR alpha), was identified. Twenty-one ligand-bound PPAR alpha structures have been deposited in the Protein Data Bank since 2001; however, binding modes of fibrates and physiological ligands remain unknown. Here we showthirty-four X-ray crystallographic structures of the PPAR alpha ligand-binding domain, which are composed of a Center'' and four Arm'' regions, in complexes with five endogenous fatty acids, sixfibrates in clinical use, and six synthetic PPAR alpha agonists. High-resolution structural analyses, in combination with coactivator recruitment and thermostability assays, demonstrate that stearic and palmitic acids are presumably physiological ligands; coordination to ArmIII is important for high PPAR alpha potency/selectivity of pemafibrate and GW7647; and agonistic activities of four fibrates are enhanced by the partial agonist GW9662. These results renew our understanding of PPAR alpha ligand recognition andcontribute to the molecular design of next-generation PPAR-targeted drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available